VivoSeq
Other

REM Sleep Behavior Disorder

9

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

REM sleep behavior disorder is an early-stage landscape with 9 programs across 5 companies. The most active players are Eli Lilly, Takeda, Vanda Pharmaceuticals. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Takeda logo

Takeda

1 program

ApprovedV

Vanda Pharmaceuticals

1 program

ApprovedJazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

ApprovedN

Neurim Pharmaceuticals Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 90% of 10 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Unknown status1 · 13%
Terminated1 · 13%
Not yet recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Not yet recruiting·YYale University·Phase 2·NCT06996652·108 enrolled
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Completed·AAxovant Sciences Ltd.·Phase 2·NCT02708186·34 enrolled
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
Completed·SStanford University·Phase 4·NCT04006925·24 enrolled
Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism
Completed·SSeoul National University Hospital·Phase 2·NCT02312908·40 enrolled
Study to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder
Completed·SSleep Medicine Centers of WNY·Phase 4·NCT01401413·20 enrolled
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT03675282·82 enrolled
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Terminated·AAxovant Sciences Ltd.·Phase 2·NCT02871427·80 enrolled
Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease
Unknown status·SSeoul National University Hospital·Phase 2·NCT02789592·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)